ANGLE unveils new strategy with executive reshuffle and name change to CelLBx Health
Charlie Blackie-Kelly | October 13, 2025 | News story | Business Services | Angle
ANGLE has outlined a revised business strategy centred on tighter cost management, accelerated commercial execution, and long-term sustainability. The update includes the appointment of a new chief executive, Dr Jan Groen, and a forthcoming name change to CelLBx Health.
The company, a global precision intelligence specialist, develops circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. It also provides CTC-based precision diagnostic testing for the pharmaceutical services sector and clinical diagnostics markets.
Under the revised strategy, ANGLE plans to leverage its proprietary Parsortix platform for CTC isolation by developing new applications in proteomics and genomics, and by integrating existing assays into its tumour DNA analysis workflows.
Dr Groen, currently non-executive chair, is expected to assume the role of chief executive as part of the transition. She brings more than 25 years’ experience in commercialising clinical and personalised oncology diagnostics, and has led multiple successful company turnarounds, including at Oncomethylome Science (later MDxHealth). Current chief executive Andrew Newland and finance director Ian Griffiths will continue to support the transition but are expected to step down in due course.
The company said the new name, CelLBx Health, reflects its renewed focus on CTC intelligence and broader ambitions within oncology.
CelLBx, short for circulating tumour cells obtained via liquid biopsy (LBx), “reflects a key and rapidly emerging field of healthcare innovation”, the company said in a statement. Health “underscores the company’s core mission: to support pharmaceutical companies and clinicians in improving outcomes for cancer patients”.
Related Content
ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …
INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more …
ANGLE signs commercial agreement with AstraZeneca
ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development …
